21.1 Transaction structure

The investor commits R19.0m across two tranches, R12.5m at close and R6.5m at the month-15 milestone, for 65% of the equity. Founders contribute R3.0m in cash alongside the transferring client book, for 35%. This implies a pre-money valuation of R10.2m, of which R7.2m is attributable to the founders’ contribution of relationships, sector experience and the pre-close work of specifying the plant and platform.

That founder valuation is a negotiated figure rather than a calculated one, and it is the most obviously contestable number in this document. It is not supported by an asset base or by trading history. An investor is entitled to argue it down; equally, a business whose FY2027 revenue depends almost entirely on relationships that the founders bring has to price those relationships at something.

21.2 Investor cash flows and returns

Table 40: Investor cash flow profile

No dividends are payable in any year of the plan; accumulated losses of R1.6m remain at FY2031, leaving no distributable reserves.

Table 41: Exit sensitivity — investor returns across the multiple range

Exit is assumed at 31 December 2031 on FY2031 EBITDA of R14.2m, less net debt of R7.7m. The base case assumes 5.0x.

The 5.0x base case multiple is supported by observable trading levels for small privately held printing businesses, which transact in a 4.0x to 6.0x EBITDA range depending on contracted revenue quality, customer concentration and asset condition. A business exiting FY2031 with 36 contracted programme accounts, no account above 12% of revenue and plant averaging under four years of age should transact at or above the midpoint. It would nonetheless be imprudent to underwrite above 5.0x: the buyer universe for a R68 million revenue printing business in Gauteng is not deep, and a thin buyer universe compresses multiples regardless of asset quality.

21.3 Discounted cash flow

Table 42: Discounted cash flow valuation

21.4 Which investors this suits

A plan that does not say who an opportunity is wrong for is not being useful. On the figures in this document:

• Suited — owner-operator consortium or industry buyer. An investor who can contribute production management, absorb the ramp-phase governance load and hold beyond five years captures the full benefit of the capacity headroom. The FY2031 utilisation of 54.0% means years six and seven are substantially more profitable than year five at little additional capital cost.
• Suited — patient or development capital. The employment profile, transformation pathway and manufacturing substitution case are substantive. A funder weighting these alongside a mid-teens financial return will find the case coherent.
• Suited — strategic trade investor. A print-management bureau or adjacent manufacturer acquiring owned production capability values the asset differently from a financial buyer and can justify a higher entry.
• Not suited — generalist private equity underwriting to 20%+. At 17.9% base-case IRR with no interim yield, a negative downside return and a thin exit buyer universe, this transaction does not clear a conventional buyout hurdle. It should not be presented as though it might.
• Not suited — income-seeking investors. There is no dividend in any year of the plan and no distributable reserve at FY2031.